Elaina Haeuber - Actinium Pharmaceuticals VP Operations

ATNM Stock  USD 1.21  0.13  9.70%   

VP

Elaina Haeuber is VP Operations of Actinium Pharmaceuticals
Address 100 Park Avenue, New York, NY, United States, 10017
Phone646 677 3870
Webhttps://www.actiniumpharma.com

Actinium Pharmaceuticals Management Efficiency

The company has return on total asset (ROA) of (0.3091) % which means that it has lost $0.3091 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8796) %, meaning that it created substantial loss on money invested by shareholders. Actinium Pharmaceuticals' management efficiency ratios could be used to measure how well Actinium Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of the 4th of December 2024, Return On Tangible Assets is likely to grow to -0.57. In addition to that, Return On Capital Employed is likely to grow to -0.68. At this time, Actinium Pharmaceuticals' Total Assets are very stable compared to the past year. As of the 4th of December 2024, Total Current Assets is likely to grow to about 82.2 M, while Other Assets are likely to drop 0.95.
Actinium Pharmaceuticals currently holds 2.11 M in liabilities with Debt to Equity (D/E) ratio of 0.03, which may suggest the company is not taking enough advantage from borrowing. Actinium Pharmaceuticals has a current ratio of 18.45, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Actinium Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.

Similar Executives

Found 8 records

VP Age

Steven WeissmanCognition Therapeutics
N/A
Christopher JDCassava Sciences
60
Stefan KraussExelixis
N/A
BSc MDBioXcel Therapeutics
55
Scott WilloughbySangamo Therapeutics
49
Raymond JDRigel Pharmaceuticals
56
Tracy ChienKodiak Sciences
N/A
Amy MDExelixis
57
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant or a type of cellular therapy, and for other adoptive cell therapies. The company was incorporated in 2000 and is based in New York, New York. Actinium Pharmaceuticals operates under Biotechnology classification in the United States and is traded on AMEX Exchange. It employs 32 people. Actinium Pharmaceuticals (ATNM) is traded on NYSE MKT Exchange in USA. It is located in 100 Park Avenue, New York, NY, United States, 10017 and employs 49 people. Actinium Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Actinium Pharmaceuticals Leadership Team

Elected by the shareholders, the Actinium Pharmaceuticals' board of directors comprises two types of representatives: Actinium Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Actinium. The board's role is to monitor Actinium Pharmaceuticals' management team and ensure that shareholders' interests are well served. Actinium Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Actinium Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Bernie PMP, Executive Management
Qing Liang, VP Sciences
Madhuri MD, Vice Therapy
Lynn MBA, Chief Officer
Paul Esq, Vice Counsel
Jenny Hsieh, Chief Officer
Dr MS, VP Operations
Sunitha Lakshminarayanan, Head VP
Mamata Gokhale, Vice President Global Head of Regulatory Affairs
Arun Swaminathan, Chief Officer
Elaina Haeuber, VP Operations
MS MBA, Chairman CEO
Caroline Yarbrough, Chief Officer
J Simeon, Executive Assurance
David Gould, Senior Affairs
Steven BS, CFO Secretary
MBA MS, Chairman CEO
Avinash MD, Chief Officer

Actinium Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Actinium Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Actinium Pharmaceuticals is a strong investment it is important to analyze Actinium Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Actinium Pharmaceuticals' future performance. For an informed investment choice regarding Actinium Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Actinium Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
To learn how to invest in Actinium Stock, please use our How to Invest in Actinium Pharmaceuticals guide.
You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Actinium Pharmaceuticals. If investors know Actinium will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Actinium Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.39)
Revenue Per Share
0.003
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.31)
Return On Equity
(0.88)
The market value of Actinium Pharmaceuticals is measured differently than its book value, which is the value of Actinium that is recorded on the company's balance sheet. Investors also form their own opinion of Actinium Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Actinium Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Actinium Pharmaceuticals' market value can be influenced by many factors that don't directly affect Actinium Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Actinium Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Actinium Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Actinium Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.